Idt Australia Ltd has released a press release.
CMAX - Opening of new Clinical Trial Facility
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from IDT Australia
- FDA Approval for Temozolomide
- Reinstatement to Official Quotation
- Manufacturing partner appointed
- Thiotepa - Contract Extension and Revenues
- $6m Placement to Accelerate IDTs Generic Drug Portfolio
Later from IDT Australia
- Completion of private placement
- Awarded Future Industries Manufacturing Program Grant
- Cancellation of shares
- Trading halt
- IDT Divests CMAX Clinical Trial Business to Irom Group
Follow IDT Australia into a list and get an email when it puts out news.
Follow IDT Australia